A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

This study is testing a new oncolytic virus treatment called R130 — a virus that is engineered to infect and kill cancer cells — by injecting it directly into tumors in people with advanced bone or soft tissue cancers (sarcomas) who have not responded to standard treatments. **You may be eligible if...** - You are 16 to 75 years old - You have been diagnosed with a soft tissue sarcoma or bone cancer confirmed by lab testing - Standard treatments have not worked, or you are unwilling or unable to receive other treatments - You have at least one tumor that can be injected directly and is measurable on imaging - You are in good general health (ECOG 0-2) and expected to live at least 3 months - All cancer treatments (chemotherapy, radiation, etc.) stopped at least 28 days before enrollment - Your blood counts, kidney, and liver functions are within acceptable levels **You may NOT be eligible if...** - You have received cancer treatment within the last 28 days - You cannot use reliable contraception if of childbearing potential Talk to your doctor to see if this trial is right for you.